Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
Sponsor: ProGen. Co., Ltd.
Summary
This is a Phase 2, therapeutic exploratory study designed to evaluate the safety and efficacy of PG-102 compared with placebo. Part A includes Cohort A, comprising participants with type 2 diabetes mellitus (T2DM). Part B includes two cohorts: Cohort B1, enrolling participants with obesity, and Cohort B2, enrolling participants with both obesity and T2DM.
Official title: A Phase II Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Safety of PG-102(MG12) Compared With Placebo in Subjects With Obesity and in Subjects With Type 2 Diabetes Mellitus (T2DM)
Key Details
Gender
All
Age Range
19 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2024-12-05
Completion Date
2025-10-30
Last Updated
2025-07-11
Healthy Volunteers
No
Interventions
PG-102
* Participants will receive PG-102 by subcutaneous (SC) injection. * Other Names: MG12
Placebo
Participants will receive placebo by SC injection
Locations (14)
The Catholic University of KOREA, Bucheon St.Mary's Hostital
Bucheon-si, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Daejeon Eul Ji Medical Center, Eul Ji University
Daejeon, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Kangbuk Samsung Hospital, Samsung Medical Center
Seoul, South Korea
KOREA University Anam Hospital
Seoul, South Korea
KOREA University Asan Hospital
Seoul, South Korea
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Kyung Hee University, Medical Center
Seoul, South Korea
Nowon Eul Ji Medical Center, Eul Ji University
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Severance Hostital
Seoul, South Korea
The Catholic University of KOREA, Seoul St.Mary's Hostital
Seoul, South Korea
The Catholic University of KOREA, Yeouido St.Mary's Hostital in Korea
Seoul, South Korea